20240051948. ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE simplified abstract (Petra Pharma Corporation)

ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE

Organization Name

Petra Pharma Corporation

Inventor(s)

Erin Danielle Anderson of Arvada CO (US)

Sean Douglas Aronow of Boulder CO (US)

Nicholas A. Boyles of Hillsboro OR (US)

Surendra Dawadi of Longmont CO (US)

Eugene R. Hickey of Danbury CT (US)

Thomas Combs Irvin of Erie CO (US)

Edward A. Kesicki of New York NY (US)

Gabrielle R. Kolakowski of Durango CO (US)

Jennifer Lynn Knight of Jersey City NJ (US)

Manoj Kumar of Broomfield CO (US)

Katelyn Frances Long of Lafayette CO (US)

Christopher Glenn Mayne of Boulder CO (US)

Alfredo Picado of Superior CO (US)

Gerit Maria Pototschnig of San Diego CA (US)

Michael Brian Welch of Westminster CO (US)

Tien Widjaja of Lafayette CO (US)

Xiaohong Chen of Broomfield CO (US)

Nathan Edward Wright of San Diego CA (US)

Hua-Yu Wang of Chula Vista CA (US)

ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240051948 titled 'ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE

Simplified Explanation

The abstract of the patent application describes a group of compounds and their pharmaceutically acceptable salts. The application also includes methods of making and using these compounds.

• The patent application describes a group of compounds and their pharmaceutically acceptable salts.
• The compounds are defined by certain variables (r, r, r, r, r, r, r, r, and r) as specified in the application.
• The application also includes methods for producing and utilizing these compounds.
• The compounds and their salts have potential applications in the field of pharmaceuticals.
• The technology described in the patent application solves certain problems in the pharmaceutical industry.
• The benefits of this technology include potential therapeutic uses and improved drug development processes.

Original Abstract Submitted

or pharmaceutically acceptable salts thereof wherein r, r, r, r, r, r, r, r, and r, are as defined herein. the disclosure also relates to methods of making and using compounds of formula (i) or pharmaceutically acceptable salts thereof.